Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy
Data for the detection and monitoring of key predictive biomarkers
for patients with newly diagnosed or progressing metastatic lung cancer
on therapy to be presented at the
"The results of this study further demonstrate the ability of Biocept's
liquid biopsy platforms to detect the presence of key cancer-associated
biomarkers, which can be used in aiding medical decision-making," said
Senior Vice President and Senior Medical Director
"The ability of the Target-Selector™ assay to detect rare genetic events
from blood has great utility when applied to patients with lung cancer,
where it is often challenging to obtain a tissue sample," said Senior
Vice President and Chief Scientific Officer
The abstract, titled "High Sensitivity Detection of Rare EGFR Mutations
with ctDNA Using Target-Selector Assays," will be featured in a poster
presentation (ST 84) on
Determining the presence of circulating tumor DNA (ctDNA) in blood, which is indicative of the presence of solid tumors, is the goal of assays known as "liquid biopsies." The use of a liquid biopsy is proving useful for monitoring a patient's tumor burden and for guiding the personalized treatment of patients with cancer based on the presence of biomarkers associated with solid tumors. Historically, solid tumor tissue obtained from surgical biopsies has been used routinely to detect the presence of key genomic biomarkers that can aid in the detection of cancer and in treatment decision-making. The ability to detect these same biomarkers based on material shed from the tumor into the blood provides an alternative for physicians where a solid tumor biopsy is difficult or impractical to obtain, or poses a high risk to the patient.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the use of liquid biopsy
generally and the use of our liquid biopsy assays by physicians, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors as
set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105005048/en/
Investors:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media